JP2022511335A5 - - Google Patents

Info

Publication number
JP2022511335A5
JP2022511335A5 JP2021515543A JP2021515543A JP2022511335A5 JP 2022511335 A5 JP2022511335 A5 JP 2022511335A5 JP 2021515543 A JP2021515543 A JP 2021515543A JP 2021515543 A JP2021515543 A JP 2021515543A JP 2022511335 A5 JP2022511335 A5 JP 2022511335A5
Authority
JP
Japan
Prior art keywords
composition
composition according
poloxamer
mmol
artificial tear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021515543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511335A (ja
Filing date
Publication date
Priority claimed from US16/137,738 external-priority patent/US20190021990A1/en
Priority claimed from US16/372,625 external-priority patent/US11583496B2/en
Priority claimed from US16/372,596 external-priority patent/US20190225917A1/en
Priority claimed from US16/372,582 external-priority patent/US20190224136A1/en
Priority claimed from US16/412,943 external-priority patent/US20190262290A1/en
Application filed filed Critical
Priority claimed from PCT/US2019/051825 external-priority patent/WO2020061249A2/en
Publication of JP2022511335A publication Critical patent/JP2022511335A/ja
Publication of JP2022511335A5 publication Critical patent/JP2022511335A5/ja
Pending legal-status Critical Current

Links

JP2021515543A 2018-09-21 2019-09-19 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法 Pending JP2022511335A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US16/137,738 2018-09-21
US16/137,738 US20190021990A1 (en) 2016-10-12 2018-09-21 Artificial tear compositions and methods of use thereof
US16/372,625 2019-04-02
US16/372,596 2019-04-02
US16/372,625 US11583496B2 (en) 2016-10-12 2019-04-02 Drug vehicle compositions and methods of use thereof
US16/372,596 US20190225917A1 (en) 2016-10-12 2019-04-02 Contact lens compositions and methods of use thereof
US16/372,582 2019-04-02
US16/372,582 US20190224136A1 (en) 2016-10-12 2019-04-02 Artificial tear compositions and methods of use thereof
US16/412,943 2019-05-15
US16/412,943 US20190262290A1 (en) 2016-10-12 2019-05-15 Drug vehicle compositions and methods of use thereof
PCT/US2019/051825 WO2020061249A2 (en) 2018-09-21 2019-09-19 Artificial tear, contact lens and drug vehicle compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2022511335A JP2022511335A (ja) 2022-01-31
JP2022511335A5 true JP2022511335A5 (cg-RX-API-DMAC7.html) 2022-09-28

Family

ID=69887791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021515543A Pending JP2022511335A (ja) 2018-09-21 2019-09-19 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法

Country Status (6)

Country Link
EP (1) EP3853317A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022511335A (cg-RX-API-DMAC7.html)
CN (1) CN113227304A (cg-RX-API-DMAC7.html)
BR (1) BR112021005097A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112278A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020061249A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
MX2023010372A (es) * 2021-03-10 2023-09-12 Bausch & Lomb Ireland Ltd Soluciones oftálmicas.
US12397518B2 (en) * 2021-04-29 2025-08-26 Coopervision International Limited WS12-releasing contact lens
CN115671256B (zh) * 2021-07-30 2024-04-09 四川大学华西医院 环孢素a与地夸磷索钠联合使用在制备治疗干眼症的药物中的用途
CN118696254B (zh) * 2022-10-31 2026-01-13 库博光学国际有限公司 释放ws12的隐形眼镜
CN117338787A (zh) * 2023-11-24 2024-01-05 南京恒道医药科技股份有限公司 一种眼用药物组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1321144E (pt) * 2000-09-13 2011-03-10 Santen Pharmaceutical Co Ltd Colírio
JP5525816B2 (ja) * 2007-09-14 2014-06-18 ロート製薬株式会社 眼科用組成物
TWI620569B (zh) * 2009-12-15 2018-04-11 遠景生物製藥股份有限公司 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
US20140377210A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Artificial tear compositions
US8597629B1 (en) * 2013-06-21 2013-12-03 Premium Ocular Solutions LLC. Artificial tear compositions comprising a combination of nonionic surfactants
HUE048564T2 (hu) * 2015-01-26 2020-08-28 Bausch & Lomb Szemészeti szuszpenzió készítmény
JP7324566B2 (ja) * 2015-05-28 2023-08-10 ロート製薬株式会社 水性眼科組成物
CA3285799A1 (en) * 2016-10-12 2025-11-29 Ps Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2018021007A5 (cg-RX-API-DMAC7.html)
JP2016534153A5 (cg-RX-API-DMAC7.html)
JP2011513492A5 (cg-RX-API-DMAC7.html)
AR107014A1 (es) Formulación farmacéutica acuosa
MX384021B (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
JP2014139241A5 (cg-RX-API-DMAC7.html)
JP2017527623A5 (cg-RX-API-DMAC7.html)
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
RU2017146716A (ru) Способ образования наночастиц циклоспорина а/ циклодекстрина
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
AR065886A1 (es) Producto de cuidado bucal y metodos de uso y fabricacion del mismo
JP2015518006A (ja) キシリトール系の抗粘膜組成物及び関連する方法並びに組成物
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
HRP20200940T1 (hr) Otopina za oralnu rehidraciju i njene metode
JP2017535616A5 (cg-RX-API-DMAC7.html)
JP2022003099A5 (cg-RX-API-DMAC7.html)
JP2017002035A5 (cg-RX-API-DMAC7.html)
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
JP2018532806A5 (cg-RX-API-DMAC7.html)
RU2018112239A (ru) Фармацевтическая композиция на основе трамадола для офтальмологического применения
JP2013535472A5 (cg-RX-API-DMAC7.html)
JP2020533336A5 (cg-RX-API-DMAC7.html)
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
RU2013140665A (ru) Композиции для ухода за полостью рта
AR115734A1 (es) Composiciones oftálmicas que contienen una prostamida liberadora de óxido nítrico